Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability
About this episode
Shamit Shrivastava discusses his innovative approach to assessing the developability of complex antibody formats in drug development.
As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocki...
Topics covered
- antibody biophysics
- drug development
- developability assessment
- interdisciplinary innovation
- Liquid Brain
More episodes of The Chain: Protein Engineering Podcast
- Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
- Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
- Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
- Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
- Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
- Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs
Explore listener stats, chart rankings, contacts and more on the The Chain: Protein Engineering Podcast podcast page.